Pemphigus Foliaceus in Dogs: Autoimmune Skin Disease Management

Pemphigus foliaceus is the most common autoimmune skin disease in dogs, causing painful crusting skin lesions that require long-term immunosuppressive management with significant welfare implications.

Key Facts

Pemphigus foliaceus involves autoimmune attack on desmoglein-1, a protein that holds skin cells together
Lesions typically begin at the nose, face, and footpads before spreading more widely
The condition causes painful crusting, erosions, and hair loss that can affect large body surface areas
Chow Chows, Akitas, Dachshunds, and Beagles are among the most commonly affected breeds
Treatment requires immunosuppressive medications including corticosteroids and often azathioprine or cyclosporine
The condition is chronic and rarely cured - most dogs require lifelong medication management

Welfare Considerations

Pemphigus foliaceus creates sustained welfare burden through both the disease itself and its treatment. Active disease causes pain and discomfort from extensive skin erosions and secondary infections; affected footpads make walking painful. The immunosuppressive treatment necessary to control the condition suppresses the immune system more broadly, increasing susceptibility to infections including bacterial skin infections, urinary tract infections, and demodicosis. Long-term corticosteroid use produces its own welfare costs: increased appetite and thirst, muscle wasting, susceptibility to infection, and the development of iatrogenic Cushing's syndrome. The appearance of severely affected dogs is confronting, sometimes leading to social isolation and reduced quality of social interactions - a welfare impact beyond the direct physical disease effects. Managing the balance between adequate immunosuppression to control the disease and minimizing medication side effects requires ongoing veterinary partnership.

What You Can Do

Seek veterinary dermatology specialist assessment for confirmed pemphigus foliaceus
Monitor for signs of secondary infection during immunosuppressive therapy: increased discharge, odor, or worsening lesions
Use barrier protection on footpads (dog boots) during active disease flares to reduce pain during walking
Discuss steroid-sparing agents (azathioprine, cyclosporine) to minimize long-term corticosteroid exposure
Schedule regular bloodwork to monitor for immunosuppression-related complications
Maintain excellent skin hygiene with appropriate gentle antiseptic bathing to reduce secondary infection burden